Income Statement (Annual)

ARLP / Alliance Resource Partners, L.P. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues
  Revenues 1,231,031 1,610,065 1,843,560 - - - - - -
Operating Costs And Expenses
  Cost Of Goods Sold Excluding Depreciation Depletion And Amortization 797,527 1,009,935 1,131,750 1,303,291 1,398,763 1,383,360 1,377,053 1,138,848 1,095,167
  Outside Coal Purchases 7,524 17,078 54,280 38,607 2,030 14 327 1,514 -
  General And Administrative Expense 41,117 50,818 52,334 58,737 63,697 72,552 67,484 72,529 61,760
  Depreciation Depletion And Amortization 117,524 146,881 160,335 218,122 264,911 274,566 333,713 322,509 268,981
  Gain Loss Related To Litigation Settlement - - - - - - - - -
  Costs And Expenses 1,009,425 1,258,296 1,430,638 1,659,822 1,762,043 1,756,513 1,912,304 1,565,511 1,467,608
Operating Income Loss 221,606 351,769 412,922 374,479 443,518 544,208 361,429 365,942 328,612
Interest Expense 30,847 30,062 21,954 28,684 27,044 33,584 31,153 30,669 39,385
Investment Income Interest 1,049 200 375 229 962 1,671 1,459 10 94
Income Loss From Equity Method Investments - - -3,404 -14,650 -24,441 -16,648 -49,046 3,543 13,860
Investment Income Dividend - - - - - - - - 6,398
Other Nonoperating Income Expense - - - - - - - - -
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest - 322,758 388,922 334,489 394,886 497,213 306,192 339,551 304,411
Income Tax Expense Benefit 708 1,741 -431 -1,082 1,396 - 21 13 210
Profit Loss 192,347 321,017 389,353 335,571 393,490 497,213 306,171 339,538 304,201
Net Income Loss Attributable To Noncontrolling Interest 190 - - - - -16 -27 140 563
Net Income Loss 192,157 321,017 389,353 335,571 393,490 497,229 306,198 339,398 303,638
Net Income Loss Allocated To General Partners 60,639 -73,172 86,251 -106,837 -121,349 -138,274 146,338 80,911 21,904
Net Income Loss Allocated To Limited Partners 131,518 247,845 303,102 228,734 272,141 358,955 159,860 258,487 281,734
Net Income Loss Per Outstanding Limited Partnership Unit Basic Net Of Tax - - - - 0 0 0 0 0
Net Income Loss Net Of Tax Per Outstanding Limited Partnership Unit Diluted - - - - 0 0 0 0 0
Distributions Per Limited Partnership Unit Outstanding 0 0 0 0 0 0 0 0 0
Weighted Average Limited Partnership Units Outstanding - - - - 73,904 74,044 74,174 74,354 98,708
Weighted Average Limited Partnership Units Outstanding Diluted - - - - 73,904 74,044 74,174 74,354 98,708

Peers - Bituminous Coal and Lignite Surface Mining (1221)

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CUSIP: 01877R108